Encouraging adaptive designs in NiHR funded clinical trials Professor Sallie Lamb Chair, CET Board.

11
Encouraging adaptive designs in NiHR funded clinical trials Professor Sallie Lamb Chair, CET Board

Transcript of Encouraging adaptive designs in NiHR funded clinical trials Professor Sallie Lamb Chair, CET Board.

Encouraging adaptive designs in NiHR funded clinical trials

Professor Sallie Lamb

Chair, CET Board

Welcome and Housekeeping

• Bathroom facilities

• Break-out areas

• Coffee and lunch

• Fire alarm and drill

• Travel expenses

• Queries

Adaptive designs

• Most discussion has arisen from drug development and approval trials

• Most guidance is provided within this context

• Most methodological development has also been within this context

• Fit for purpose for NiHR trials (HTA) ?

• When indicated ?

• How facilitated ?

Adaptive designs

• Covers many different types of adaptation

• Futility and early stopping

• Treatment selection

• Dose response

• Sub-group refinement

• Interim sample size re-estimation

Adaptive designs

• Some applications not well understood

• Many myths – around speed, cost and method

• Widely accepted that operational issues are as important as statistical issues

NiHR funded research is different

• NiHR HTA programme – largest funder of academic clinical trials in the UK – pragmatic, phase III

• Commissioned and responsive mode

• NiHR EME programme – phase II/mechanistic

• NiHR programme grants

• NiHR fellowship applications

Trial phases

Pharmaceutical Industry HTA

To demonstrate superiority, or equivalence/n-i with better safety profile

To estimate superiority, equivalence, n-i with better safety profile

Risk of accepting null hypothesis to be minimised or eliminated prior to Phase III

Usually no risk to accepting null hypothesis - value of information remains high and investment worthwhile*

Drug trials for regulatory approval Few trials to support regulatory approval

Main driver of design – companies/regulator

Main driver of design – academics/funder

Outcomes - disease specific as primary

Various layers of outcome – disease specific, generic HQoL, cost

Comparators – placebo and/or active control

Comparators – usual care/ best current practice

Maximise effect prior to Phase III (a) Evaluate effect in everyday settings

O P E R A

OLDER PEOPLE’S EXERCISE IN RESIDENTIAL ACCOMMODATION

So what is today about

• Identify the issues• Methodological• Logistical – recruitment, ethics• Logistical - funding arrangements*• Talks – stats, trialist, and economics• Discussion – stick-its, group work• Workshops• Dissemination

Workshops

• What are the (applied) methodological questions that need to be addressed?

• What are the practical/organisational implications of using adaptive designs?

• What guide can we give for when adaptive designs should be considered?

• How should we encourage the greater use of adaptive designs in NiHR research?